Ventyx biosciences announces results from the phase 2 trial of vtx958 in patients with moderate to severe plaque psoriasis and provides corporate update

Vtx958 225 mg bid and 300 mg bid doses achieved statistical significance on the primary endpoint (pasi 75) and all key secondary endpoints at week 16

VTYX Ratings Summary

VTYX Quant Ranking